Clinical Trial
doi: 10.1016/0092-1157(89)90031-0.
Mumps vaccine L-Zagreb, prepared in chick fibroblasts. I. Production and field trials
Affiliations
- PMID: 2646300
- DOI: 10.1016/0092-1157(89)90031-0
Item in Clipboard
Clinical Trial
Mumps vaccine L-Zagreb, prepared in chick fibroblasts. I. Production and field trials
J Biol Stand.
1989 Jan.
Abstract
Leningrad-L3 Mumps Vaccine virus has been further attenuated by adaptation and passage on SPF chick embryo fibroblast cell cultures. This new mumps strain has been designated L-Zagreb and has been used to prepare mumps vaccines which meet the WHO requirements. Observations during both the field trial period prior to registration and during the later use of the vaccine showed that the few reactions observed were mild and that seroconversion was obtained in 88-98% of vaccines. The morbidity of mumps in Croatia declined more than tenfold after the introduction of the new vaccine. During a mumps epidemic, vaccine efficiency was calculated to be 97-100%.
Similar articles
-
Measles, mumps, rubella, and varicella.Lancet. 1990 Jun 9;335(8702):1384-7. doi: 10.1016/0140-6736(90)91255-9. Lancet. 1990. PMID: 1971671 Review. No abstract available.
-
Interference between strains in live virus vaccines, I: Combined vaccination with measles, mumps and rubella vaccine.J Biol Stand. 1988 Oct;16(4):269-73. doi: 10.1016/0092-1157(88)90014-5. J Biol Stand. 1988. PMID: 3198657
-
Interference between strains in live virus vaccines. II: Combined vaccination with varicella and measles-mumps-rubella vaccine.J Biol Stand. 1988 Oct;16(4):275-9. doi: 10.1016/0092-1157(88)90015-7. J Biol Stand. 1988. PMID: 2848843
-
Comparative evaluation of two combined measles-mumps-rubella vaccines based on AIK and Edmonston- Zagreb strains of measles virus.Kitasato Arch Exp Med. 1991 Sep;64(2-3):141-7. Kitasato Arch Exp Med. 1991. PMID: 1811112
-
Rational use of measles, mumps and rubella (MMR) vaccine.Drugs. 1993 May;45(5):677-83. doi: 10.2165/00003495-199345050-00005. Drugs. 1993. PMID: 7686463 Review.
Cited by
-
Antigenic differences between vaccine and circulating wild-type mumps viruses decreases neutralization capacity of vaccine-induced antibodies.Epidemiol Infect. 2013 Jun;141(6):1298-309. doi: 10.1017/S0950268812001896. Epub 2012 Sep 7. Epidemiol Infect. 2013. PMID: 22954346 Free PMC article.
-
The F gene of rodent brain-adapted mumps virus is a major determinant of neurovirulence.J Virol. 2007 Aug;81(15):8293-302. doi: 10.1128/JVI.00266-07. Epub 2007 May 2. J Virol. 2007. PMID: 17475640 Free PMC article.
-
Vaccines for measles, mumps, rubella, and varicella in children.Cochrane Database Syst Rev. 2021 Nov 22;11(11):CD004407. doi: 10.1002/14651858.CD004407.pub5. Cochrane Database Syst Rev. 2021. PMID: 34806766 Free PMC article. Review.
-
Immunogenicity of mumps virus vaccine candidates matching circulating genotypes in the United States and China.Vaccine. 2017 Jul 13;35(32):3988-3994. doi: 10.1016/j.vaccine.2017.05.084. Epub 2017 Jun 13. Vaccine. 2017. PMID: 28623030 Free PMC article.
-
Vaccines for measles, mumps and rubella in children.Cochrane Database Syst Rev. 2012 Feb 15;2012(2):CD004407. doi: 10.1002/14651858.CD004407.pub3. Cochrane Database Syst Rev. 2012. Update in: Cochrane Database Syst Rev. 2020 Apr 20;4:CD004407. doi: 10.1002/14651858.CD004407.pub4 PMID: 22336803 Free PMC article. Updated. Review.